Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: The authors' reply

dc.creatorBernal T.
dc.creatorMartínez-Camblor P.
dc.creatorSánchez-García J.
dc.creatorSanz G.
dc.date.accessioned2020-09-02T22:13:07Z
dc.date.accessioned2022-11-08T20:23:04Z
dc.date.available2020-09-02T22:13:07Z
dc.date.available2022-11-08T20:23:04Z
dc.date.created2020-09-02T22:13:07Z
dc.date.issued2016
dc.identifier30, 3, 740-741
dc.identifier08876924
dc.identifierhttps://hdl.handle.net/20.500.12728/3739
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5144684
dc.languageen
dc.publisherNature Publishing Group
dc.titleEffectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: The authors' reply
dc.typeLetter


Este ítem pertenece a la siguiente institución